<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01583023</url>
  </required_header>
  <id_info>
    <org_study_id>RTMS-BD-1</org_study_id>
    <nct_id>NCT01583023</nct_id>
  </id_info>
  <brief_title>Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression</brief_title>
  <official_title>Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether repetitive transcranial magnetic stimulation
      (rTMS) treatment is an effective adjunct treatment to mood stabilizers and Bupropion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Montgomery-Asberg Depression Rating Scale (MADRS) from baseline at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Beck Depression Inventory (BDI-II) from baseline at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Young Mania Rating Scale (YMRS) from baseline at 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol use disorder identification test (AUDIT Assessment)</measure>
    <time_frame>At intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug abuse screen test (DAST Assessment)</measure>
    <time_frame>At intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) &amp; Analog scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Sham rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Lithium a/o Epival + Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>150mg daily for first week, 300mg daily thereafter for a total of 8 weeks</description>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Sham rTMS</arm_group_label>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Active rTMS</arm_group_label>
    <other_name>Wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Repetitive Transcranial Magnetic Stimulation</intervention_name>
    <description>Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.</description>
    <arm_group_label>Placebo + Lithium a/o Epival + Active rTMS</arm_group_label>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Active rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>150mg daily first week, 300mg daily thereafter for a total of 8 weeks.</description>
    <arm_group_label>Placebo + Lithium a/o Epival + Active rTMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham repetitive transcranial magnetic stimulation</intervention_name>
    <description>Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.</description>
    <arm_group_label>Wellbutrin + Lithium a/o Epival + Sham rTMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BD Type I or II subjects diagnosed according to the Diagnostic and Statistical Manual of
        Mental Disorders (DSM-IV) in depressed phase.

        Age 18 to 70. Rating on the Montgomery-Asberg Depression Rating Scale (MADRS) score &gt; 20.
        Rating on the Beck Depression Inventory (BDI-II) &gt; 20. Rating on the Young Mania Rating
        Scale (YMRS) &lt; 8. Non-treated new depressive episode, at least 2 weeks in duration. If
        recently started on an antidepressant other than Wellbutrin, subject must spend at least 4
        weeks at a therapeutic dose before entering the study.

        Lithium and epival (Sodium Valproate) in monotherapy or in combination. Novel
        antipsychotics can be combined with mood stabilizers for at least 4 weeks at a steady
        dosage prior to the study.

        Exclusion Criteria:

        History of any DSM-IV Axis I diagnosis other than BD Type I or II Presence of any psychotic
        symptoms, characterized by a score of 3 or more on item 10 of the MADRS, a score of 6 on
        item 9 of the MADRS, or a score of 6 or more on item 8 of the YMRS Comorbid active
        dependence or substance abuse (except nicotine) Prior electroconvulsive therapy failure
        Pacemaker, automatic implantable defibrillator or implantable pump Aneurysm Clip
        Heart/Vascular Clip Prosthetic Valve Metal Prosthesis Pregnancy (must do a blood Î²-HCG test
        to exclude) Metal or metal fragments in the head Personal or Family history of seizure
        disorder Increased Intracranial pressure History of stroke, meningitis/encephalitis,
        moderate to severe traumatic brain injury, neurosurgical procedure Pharmacotherapy using
        any substances not mentioned in the inclusion criteria, except benzodiazepines at an
        equivalent dose of less than or equal to 1mg/day of lorazepam.

        Failure of previous Wellbutrin treatment. Mood disorder secondary to a medical condition.
        Subject currently enrolled in any detoxification program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Cervanes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore Kolivakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy CP Low, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriella Gobbi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pablo Cervantes, MD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>36109</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Allan Memorial Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pablo Cervantes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Kolivakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy CP Low, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Ptito, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriella Gobbi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maykel F.Ghabrash, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2012</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Pablo Cervantes</investigator_full_name>
    <investigator_title>Director of the Mood Disorders Clinic</investigator_title>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>repetitive transcranial magnetic stimulation (rtms)</keyword>
  <keyword>bupropion</keyword>
  <keyword>lithium a/o Epival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

